Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
1 | Acute myeloid leukemia |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
2 | AGE-RAGE signaling pathway in diabetic complications |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
3 | Axon guidance |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
4 | Bladder cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
5 | Breast cancer |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
6 | Calcium signaling pathway |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
7 | Cell cycle |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
8 | Central carbon metabolism in cancer |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
9 | Choline metabolism in cancer |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
10 | Chronic myeloid leukemia |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
11 | EGFR tyrosine kinase inhibitor resistance |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
12 | Endocytosis |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
13 | ErbB signaling pathway |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
14 | Fluid shear stress and atherosclerosis |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
15 | Focal adhesion |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
16 | Gap junction |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
17 | Glioma |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
18 | Hematopoietic cell lineage |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
19 | HIF-1 signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
20 | Human cytomegalovirus infection |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
21 | Human papillomavirus infection |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
22 | JAK-STAT signaling pathway |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
23 | Kaposi sarcoma-associated herpesvirus infection |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
24 | MAPK signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
25 | Melanogenesis |
[1] KIT | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
26 | Melanoma |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
27 | MicroRNAs in cancer |
[2] ABL1, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
28 | Neurotrophin signaling pathway |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
29 | Pancreatic cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
30 | Pathogenic Escherichia coli infection |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
31 | Pathways in cancer |
[3] ABL1, KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
32 | Phospholipase D signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
33 | PI3K-Akt signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
34 | Prostate cancer |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
35 | Proteoglycans in cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
36 | Rap1 signaling pathway |
[2] KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
37 | Ras signaling pathway |
[3] ABL1, KIT, PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
38 | Regulation of actin cytoskeleton |
[1] PDGFRA | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
39 | Relaxin signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
40 | Renal cell carcinoma |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
41 | Rheumatoid arthritis |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
42 | Shigellosis |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 | |||||
43 | VEGF signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
44 | Viral myocarditis |
[1] ABL1 | D01441 | Imatinib | [11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
D08066 |